IP Verse

Isis Pharmaceuticals, Inc. opposition analysis

COMPANY ANALYSIS

Latest patents of Isis Pharmaceuticals, Inc. opposed by its competitors

Patent:
EP2906696
Grant Date:
Dec 14, 2022
Title:
Methods For Modulating C9Orf72 Expression
Oppositions:
2
Patent:
EP2742135
Grant Date:
Jun 10, 2020
Title:
Linkage Modified Gapped Oligomeric Compounds And Uses Thereof
Oppositions:
1
Patent:
EP2399588
Grant Date:
Apr 29, 2020
Title:
Nucleoside Derivatives As Inhibitors Of Rna-Dependent Rna Viral Polymerase
Oppositions:
1
Patent:
EP2640853
Grant Date:
Dec 26, 2018
Title:
Modulation Of Alpha Synuclein Expression
Oppositions:
1
Patent:
EP2864479
Grant Date:
Aug 15, 2018
Title:
Modulation Of Ube3A-Ats Expression
Oppositions:
1
Patent:
EP2701713
Grant Date:
Feb 7, 2018
Title:
Modulation Of Apolipoprotein Ciii (Apociii) Expression
Oppositions:
2
Patent:
EP2812342
Grant Date:
Nov 15, 2017
Title:
Modulation Of Rna By Repeat Targeting
Oppositions:
1

Competitors of Isis Pharmaceuticals, Inc.

ROCHE INNOVATION CENTER COPENHAGEN A/S

STRAWMAN LIMITED

F.HOFFMANN-LA ROCHE AG

Want to track Isis Pharmaceuticals, Inc.?

Feel free to send us a message here and we will get back to you